Expert Exchange on Sjögren’s Disease: Uncovering Systemic Disease Burden Through ESSDAI Domains скачать в хорошем качестве

Expert Exchange on Sjögren’s Disease: Uncovering Systemic Disease Burden Through ESSDAI Domains

Discover how ESSDAI-based questions help reveal systemic involvement in Sjögren’s disease. Teja Kapoor, MD, and Adam Doré, DO, highlight key domains, including glandular, articular, cutaneous, and lymphadenopathy. 1. Carsons SE, Blum MA. Sjogren syndrome. StatPearls Publishing; 2025. National Library of Medicine. Updated July 6, 2025. Accessed September 5, 2025. https://www.ncbi.nlm.nih.gov/books/NB... 2. Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. doi:10.1038/nrdp.2016.47 3. Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi:10.1136/annrheumdis-2019-216114 4. Mariette X, Criswell LA. Primary Sjögren’s syndrome. N Engl J Med. 2018;378(10):931-939. doi:10.1056/NEJMcp1702514 5. Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022. doi:10.1136/rmdopen-2014-000022 6. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382-389. doi:10.1136/annrheumdis-2014-206008 7. Fauchais AL, Ouattara B, Gondran G, et al. Articular manifestations in primary Sjögren’s syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford). 2010;49(6):1164-1172. doi:10.1093/rheumatology/keq047 8. Brito-Zerón P, Flores-Chávez A, Horváth IF, et al. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study. EClinicalMedicine. 2023;61:102062. doi:10.1016/j.eclinm.2023.102062 9. Ma D, Feng Y, Lin X. Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren’s syndrome. Front Immunol. 2024;15:1421436. doi:10.3389/fimmu.2024.1421436 10. Retamozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus. 2019;28(8):923-936. doi:10.1177/0961203319857132 11. Sambataro G, Ferro F, Orlandi M, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev. 2020;19(2):102447. doi:10.1016/j.autrev.2019.102447 12. Stojan G, Baer AN, Danoff SK. Pulmonary manifestations of Sjögren’s syndrome. Curr Allergy Asthma Rep. 2013;13(4):354-360. doi:10.1007/s11882-013-0357-9 13. Huang H, Xie W, Geng Y, Fan Y, Zhang Z. Mortality in patients with primary Sjögren’s syndrome: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(9):4029-4038. doi:10.1093/rheumatology/keab364 14. Birt JA, Tan Y, Mozaffarian N. Sjögren’s syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options. Clin Exp Rheumatol. 2017;35(1):98-107. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2026 Novartis 3/26 FA-11597550